Novartis sees Alcon helping to drive group growth, create $350m cost synergies
This article was originally published in Clinica
Executive Summary
Novartis has issued an update on the growth prospects of the group, with its Alcon eye care business making a strong contribution. Novartis acquired the company for around $52bn in staggered transactions completed in April (www.clinica.co.uk, 8 April 2011).